Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | PGK2 | P07205 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.34 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11353068 | 0.87 | KCNN4 (0.48) | TSHRALDH1A1PTPN1KCNN4CA1 | |
| SCHEMBL1171482 | 0.85 | ESR1 (0.56) | TSHRALDH1A1PTPN1CA1CA2 | |
| SCHEMBL11359003 | 0.85 | ALDH1A1 (0.44) | TSHRALDH1A1KIF11NR1H2NR1H3 | |
| SCHEMBL1140694 | 0.85 | KIF11 (0.46) | TSHRALDH1A1KCNN4CA1CA2 | |
| SCHEMBL11357068 | 0.85 | ALDH1A1 (0.44) | TSHRALDH1A1PTPN1KCNN4CA1 | |
| SCHEMBL23894326 | 0.85 | KIF11 (0.44) | TSHRALDH1A1CA1CA2CA5A | |
| SCHEMBL11349635 | 0.85 | KIF11 (0.44) | TSHRALDH1A1CA1CA2CA5A | |
| SCHEMBL11358491 | 0.82 | LTA4H (0.50) | TSHRALDH1A1CA1CA2NR1H2 | |
| SCHEMBL11361945 | 0.80 | PTPN5 (0.46) | TSHRALDH1A1KIF11NR1H2NR1H3 | |
| SCHEMBL3472057 | 0.80 | TSHR (0.61) | TSHRALDH1A1PTPN1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576574-A2 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | Sarepta Therapeutics, Inc. (US) | 2013-04-10 | — | — | EP | claimed |
| WO-2012031243-A2 | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | AVI BIOPHARMA, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| WO-2011150408-A2 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | AVI BIOPHARMA, INC. (US) | 2011-12-01 | — | — | WO | claimed |
| US-5364917-A | Perfluorocyclobutane ring-containing polymers | THE DOW CHEMICAL COMPANY (US) | 1994-11-15 | — | — | US | claimed |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11225662-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11071749-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-11072793-B2 | DsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20210139896-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-05-13 | — | — | US | disclosed |
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| CN-107693797-B | Peptide oligonucleotide conjugates | 萨勒普塔医疗公司 | 2021-05-11 | — | — | CN | disclosed |
| US-20200277598-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-09-03 | — | — | US | disclosed |
| WO-2011150408-A2 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | AVI BIOPHARMA, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-7947791-B2 | Fluorinated polymer | ASAHI GLASS COMPANY, LIMITED (JP) | 2011-05-24 | — | — | US | disclosed |
| US-20090186986-A1 | NOVEL FLUORINATED POLYMER | ASAHI GLASS COMPANY, LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| US-7303852-B2 | Photoacid generating compounds, chemically amplified positive resist materials, and pattern forming method | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2007-12-04 | — | — | US | disclosed |
| CN-101024773-A | Liquid crystal aligning agent and liquid crystal display device | JSR CORP (JP) | 2007-08-29 | — | — | CN | disclosed |
| US-5364917-A | Perfluorocyclobutane ring-containing polymers | THE DOW CHEMICAL COMPANY (US) | 1994-11-15 | — | — | US | disclosed |
| WO-1994025505-A1 | PERFLUOROCYCLOBUTANE RING-CONTAINING POLYIMIDES | THE DOW CHEMICAL COMPANY (US) | 1994-11-10 | — | — | WO | disclosed |
| US-4307024-A | 1,1,1-Triaryl-2,2,2-trifluoroethanes and process for their synthesis | NASA | 1981-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277598-A1 | Peptide Oligonucleotide Conjugates | SNRPE, SMN1; SMN2, UPF1 | TSHR 721/4885ALDH1A1 3700/4885PTPN1 2781/4885 |
| US-11071749-B2 | Oligonucleotide analogues targeting human LMNA | LMNB2, LMNA, LMNB1 | TSHR 1863/4885ALDH1A1 4394/4885PTPN1 4829/4885 |
| US-20210139896-A1 | Peptide Oligonucleotide Conjugates | SNRPE, SMN1; SMN2, UPF1 | TSHR 721/4885ALDH1A1 3700/4885PTPN1 2781/4885 |
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | TSHR 2993/4885ALDH1A1 2803/4885PTPN1 3849/4885 |
| US-11225662-B2 | Peptide oligonucleotide conjugates | SNRPE, SMN1; SMN2, UPF1 | TSHR 721/4885ALDH1A1 3700/4885PTPN1 2781/4885 |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SNRPE, SMN1; SMN2, UPF1 | TSHR 721/4885ALDH1A1 3700/4885PTPN1 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.